Objectives: Brief intravenous administration of chimeric antibody c7E3 Fab during coronary angioplasty has been shown in some studies to provide long term protection against coronary events. Smooth muscle cell (SMC) adhesion and migration are key initial steps in the development of restenosis. The purpose of this study was to investigate the effect of c7E3 Fab on adhesion and migration of SMC to the extracellular matrix (ECM) proteins osteopontin (Opn) and vitronectin (Vn). Methods: Adhesion of human vascular SMCs to ECM proteins was quantified using a CyQUANT assay kit. Migration of SMCs to Vn, Opn and PDGF was studied using a modified Boyden's chamber migration assay. Integrin expression was determined by immunoprecipitation. Results: c7E3 Fab reduced SMC adhesion on Vn and Opn to 69.263.3% (P,0.001) and 52.564.8% (P,0.001) respectively, compared to adhesion without antibody present. This reduction was the same as that for anti-a b integrin antibody LM609 (P50.5). The combination of anti-a b integrin antibody and c7E3
Introduction
confirmed that it also binds the a b integrin [4] . This v 3 receptor is found on the surface of several cells, including Administration of c7E3 Fab (abciximab, Reo Pro) to human vascular smooth muscle cells (SMCs) [5, 6] . It is prevent thrombotic complications following percutaneous upregulated following vascular injury [7, 8] , and is incoronary interventions has been associated with long-term volved in SMC adhesion and migration [9] [10] [11] [12] [13] [14] , both of reductions in subsequent coronary events or need for which are important initial steps in the development of the revascularisation in some trials [1] . This observation led to neointimal tissue that is responsible for vessel restenosis speculation that this antibody may also influence re- [5] . Animal studies have demonstrated that blockade of the stenosis.
a b integrin after angioplasty results in reduction of v 3 Although the antibody c7E3 Fab was developed to be neointimal formation [14] [15] [16] . specific for the glycoprotein IIb / IIIa integrin expressed on
The parent IgG of c7E3 Fab, m7E3, has been shown to the surface of activated platelets [2, 3] , it has recently been reduce thrombospondin-and thrombin-induced SMC proliferation in vitro, but has no effect on PDGF-or serum-*Corresponding author. Tel.: 144-116-256-3038; fax: 144-116-287-5792.
Time for primary review 33 days.
induced proliferation [7] . c7E3 Fab has been shown to small pieces, and incubated in DMEM with 20% foetal calf reduce adhesion of a b -expressing M21 melanoma cells serum (FCS), pyruvate (0.11 g / l) and gentamicin at 378C, v 3 in vivo [4] . Its effect on human vascular SMC adhesion 5% CO . SMCs growing out of explant were sequentially 2 and migration, however, has not been reported. In this cultured in 10% FCS-containing medium. SMCs of twostudy, the influence of c7E3 Fab on adhesion and migrasix passages were used in the study. They were charactertion to SMC substrates vitronectin (Vn) and osteopontin ised by their typical hill and valley morphology at con-(Opn) was studied. Both these extracellular matrix proteins fluence, and by their staining with antibodies against SMC are present in increased quantities at the site of vascular a-actin. injury [16] [17] [18] , and are implicated in adhesion and migration processes mostly mediated via the a b integrin 2.3. Adhesion assays v 3
[9-12,16,17]. Platelet derived growth factor (PDGF) was included in the migration studies as it is an important The adhesion experiments were carried out using cells chemotactic agent following vascular injury [19] . Migraderived from the saphenous vein from one subject. These tion studies using cells not expressing the a b integrin studies were performed twice, using four wells per set of v 3 were used as a negative control. In all experiments, conditions. Ninety-six-well plates were pre-coated with 50 abciximab was studied in parallel with LM609, which is ml (100 nmol / l) of Vn or Opn at 48C overnight, blocked known to block the binding of a b , and inhibit cell with 1% bovine serum albumin (BSA) in phosphate The rat osteopontin (Opn) was kindly donated by with 0.25% BSA. Cells in suspension (10 cells in 100 ml) Smithkline-Beecham, USA. Human vitronectin (Vn) was were allowed to adhere to pretreated 96-well plates for 1 h purchased from Life Technologies. A monoclonal antibody at 378C (5% CO ). When antibodies were used, the cells 2 against smooth muscle cell a-actin (1A4) was purchased were preincubated with antibodies for 30 min at 378C and from Sigma Bioscience. The c7E3 Fab was kindly donated allowed to adhere in their presence. Antibodies were used by Centocor, USA. Mouse monoclonal antibodies against at a concentration of 10 mg / ml, except for the varied dose human a b integrin (MAB1976, clone LM609), a b studies, where concentrations were from 0.5 to 25 mg / ml. integrin (MAB1961) and vitronectin (MAB1945) were After adhesion the medium was removed by gentle sucpurchased from Chemicon International, FITC-conjugated tion, and non-adherent cells were removed by washing F(ab9) fragment of rabbit anti-mouse immunoglobulin twice with PBS. The adhesion was quantified using a 2 (F0313) was purchased from Dako. Mouse IgG (k) CyQUANTE nucleic acid fluorescence assay kit (Molecu-1 antibody against trinitrophenol, (03000D, now-03191D) lar Probes). Calibration curves showed the fluorescence was used as a control irrelevant antibody in both the reading to be proportional to the cell number. adhesion and migration studies. It is marketed as a control
In further studies, the experiments performed with cells antibody by Pharmingen, and was used instead of pooled derived from saphenous vein were repeated using aortic IgG, which may have contained antibodies that interacted SMCs in order to confirm the results with arterial cells. with SMCs. It is referred to as control IgG. Mouse antihuman integrin a5 monoclonal antibody (33220D) was 2.4. Migration assays also purchased from Pharmingen, and was used in the adhesion assays as a second control as c7E3 Fab is not
The initial results of the adhesion experiments led us to thought to interact with this integrin sub-unit.
investigate SMC migration, this time focusing the effects of c7E3 Fab and LM609 on migration to Vn and Opn. 2.2. Cell culture PDGF was also included as it is one of the important chemotactic growth factors present in vivo, and we wished Human vascular SMCs were obtained from primary to find out whether c7E3 Fab was able to influence explant culture of fragments of saphenous vein or aortic migration towards it. punch biopsy obtained from patients undergoing surgery as Migration studies were conducted as described previousdescribed previously [20] . The investigation conforms with ly [11, 20] with some modifications. Confluent cells were the principles outlined in the declaration of Helsinki resuspended in serum-free DMEM with 0.25% BSA. Cells 4 (Cardiovascular Research 1997;35:2-3). Briefly, the endoin suspension (5310 cells per 100 ml) were added to the thelium was removed by gentle scraping, and the advenupper compartment of a Transwell plate (Costar, 8-mm titia was dissected away. The remaining tissue was cut into polycarbonate membrane). The lower compartment con-tained 600 ml of DMEM10.25% BSA, with Vn (20 mg / antibodies for 30 min at 378C and allowed to migrate in ml), Opn (20 mg / ml), or PDGF-BB (10 ng / ml), added their presence. Antibodies were used at a concentration of when appropriate. The concentrations of Vn, Opn and 10 mg / ml, except for the studies evaluating antibody dose PDGF-BB used were determined in preliminary expericurves, where concentrations were selected between 0.5 ments of SMC migration in the absence of antibodies, and 25 mg / ml. where all three were found to induce migration in a Finally, the antibody experiments were repeated using dose-dependent manner with a plateau being achieved at cells from an aortic source that were similar in behaviour higher concentrations. The concentrations selected were and integrin expression to those saphenous cells able to within the plateau range. The plates were incubated at migrate to Opn. 378C, 5% CO for 6 h. The upper compartment of the 2 chamber insert was rinsed with PBS, and the cells were 2.5. Statistical analysis fixed in 4% paraformaldehyde at room temperature for 20 min. Cells on the upper surface of the membrane were All data are represented as mean6standard deviation. removed by gentle wiping. The inserts were incubated with
Comparison of the effect of antibodies within a treatment 20 mg / ml of propidium iodide (Molecular Probes) in the group was performed using one-way ANOVA. Comparison presence of ribonuclease A (0.2 mg / ml) for 30 min at of the effect of c7E3 Fab (versus no antibody) in different 378C to stain cell nuclei. The membranes were mounted on experiments was performed using two-way ANOVA. All glass slides and the number of migrating cells was analyses were performed using SPSS version 9. P-values averaged over five 3200 power fields per membrane. All were adjusted for multiple testing, but statistical signifiexperiments were performed at least twice, using three cance was interpreted with caution. inserts for each set of conditions.
Preliminary migration studies and

Results immunoprecipitation
The early observation that the cells from one particular 3.1. SMC adhesion saphenous vein did not migrate significantly to Opn led to experiments being performed to characterise the integrin The experiments set out to determine the effect of c7E3 expression of the cells. Immunoprecipitation was carried Fab on SMC adhesion. Several commercial antibodies out on these cells, and compared to immunoprecipitation inhibiting cell adhesion were included in this study in of SMCs from a saphenous vein culture that did migrate to parallel with c7E3 Fab. The antibody LM609, known to Opn.
inhibit cell adhesion to Vn by blocking a b integrin, was times with PBS, and dissolved and scraped in RIPA buffer, included as negative controls. containing 10 mM Tris-Cl, pH 7.0, 150 mM NaCl, 2 mM
The adhesion experiments described in Sections 3.1.1 EDTA, 0.1% SDS, 1% NP40, 1% sodium deoxycholate, and 3.1.2 (below) were carried out using SMCs derived protease inhibitors cocktail (Sigma), followed by centrifufrom saphenous vein from one subject (Figs. 1 and 2). gation to remove cellular debris. Protein extracts con- 35 7 taining equal amounts of S-labelled proteins (10 cpm) 3.1. to both Vn and Opn was observed in the range of antibody SDS-PAGE and detected by autoradiography on X-OMAT concentrations from 2 to 25 mg / ml, therefore we used film (Kodak) according to standard procedures [21] .
antibody concentration 10 mg / ml in further experiments. Cells derived from these two saphenous vein sources c7E3 Fab decreased SMC adhesion to Opn to a greater were also compared for their ability to migrate to Vn and extent than to Vn (Figs. 1 and 2) (P50.002). Neither PDGF.
antibody reduced adhesion to the levels seen on untreated plastic wells (which was approximately 25-30% of adhe-2.4. sources was compared. The cells were preincubated with antibodies reduced adhesion significantly (P50.5 and 0.3 respectively for Vn, and P50.75 and 0.08 respectively for Opn). Using 10 mg / ml of antibody, cell adhesion on vitronectin was reduced to 69.263.3% (P,0.001) by c7E3 Fab, and 71.167.6% (P,0.001) by LM609, when compared to adhesion without antibody inhibition (Figs. 1and 2. ). There was no significant difference between the effect of c7E3 Fab and LM609 (P50.5).
Adhesion on osteopontin was reduced to 52.564.8% (P,0.001) by c7E3 Fab, and 50.164.8% (P,0.001) by LM609 (Fig. 2) . Again, there was no significant difference between the effect of c7E3 Fab and LM609 (P50.4).
Combining c7E3 Fab with LM609 in the same experiment (10 mg / ml of each) did not inhibit adhesion to a greater extent than either antibody alone (Fig. 2) Vn and Opn to a similar degree to c7E3 Fab or LM609 (Fig. 2. ) However, whereas the addition of LM609 to c7E3 Fab showed no further reduction in SMC adhesion, the antibodies for Vn and 0.5 mg / ml of antibodies for Opn (* P,0.05).
Adhesion of SMCs derived from an arterial source is also reduced by abciximab and LM609
We also compared the effect of LM609 and c7E3 Fab on SMCs derived from aorta (from another patient) with the results obtained with the saphenous vein cells (Table 1) . A similar degree of inhibition of aortic SMC adhesion was seen with the antibodies (P,0.001 for c7E3 Fab and LM609, compared with adhesion with no antibody present). No difference was seen between the influence of LM609 and c7E3 Fab (P50.7 for Vn and 0.5 for Opn). The results of the Western Blot from the immunoprecipitation experiments can be seen in Fig. 3 . A faint dependent on the expression of the a b integrin proteins much more than PDGF-induced migration. inhibited by c7E3 Fab (P50.8 and P50.9 respectively), in keeping with the hypothesis that c7E3 Fab inhibits SMC migration via this integrin alone. Opn-induced migration, and the least on PDGF-induced migration. c7E3 Fab reduced Opn-induced migration to achieved at concentrations above 5 mg / ml (data not just 25.565.2% of migration in the absence of antibody, shown). Control IgG did not significantly affect SMC but this remained significantly greater than non-induced migration.
migration in the absence of Opn (P,0.001). At a concentration of 10 mg / ml, both antibodies c7E3 Fab and LM609 significantly reduced SMC migration to PDGF, Opn and Vn (Fig. 5) around 6 mg / ml [25] . a All antibodies were used at a concentration of 10 mg / ml. The data is presented as a percentage of cell migration without antibody present (mean6S.D.).
b P,0.05 compared with migration in the absence of antibody. c Non-induced migration is migration without ECM / PDGF in the lower compartment of the migration chamber.
The adhesion experiments showed that c7E3 Fab and vascular injury in vivo would behave in a similar way to adhesion to a similar degree, suggesting they are likely to PDGF did still induce some migration. From this, we can act via the same integrin, but neither could prevent conclude that a b integrin is the major integrin respon- Opn to a greater extent than either antibody alone. Similar not inhibited by c7E3 Fab, consistent with the hypothesis findings have been reported previously with melanoma that c7E3 Fab acts via this integrin.
M21 cells, with this combination of antibodies preventing
It is interesting to note that SMC migration to PDGF significant adhesion in vitro [4] . Previous studies have was only slightly reduced by LM609 and c7E3 Fab. The shown that a b integrin is also involved in SMC adhepublished data on the role of a b integrin on PDGF- subunit are detectable ( Fig. 3A and 3B ). In this study, antibodies inhibited SMC migration to PDGF, whereas however, a b and a b integrins were mostly responsible other studies found that the inhibitory effect of anti-b was much higher than on SMC adhesion to both Vn and LM609 [13, 14] . It is feasible that the inhibitory effect of Opn, which would be expected, as cell migration occurs anti-integrin antibodies would vary according to the exthrough multiple cycles of cell attachments and detachpression of different integrins in studied cell lines. ments. It is also consistent with previously published data Our data on SMC migration to Vn also indicate other demonstrating that the a b integrin contributes to SMC receptors may be involved. Recently, urokinase-type plasv 3 migration to a greater extent than adhesion [12] . The minogen activator receptor uPAR and plasminogen acinhibitory effect of c7E3 Fab and LM609 was greater for tivator inhibitor PAI-1 were identified as Vn-binding proOpn than Vn, suggesting that the relative role of a b teins in several cell types [29, 30] . These proteins recognise v 3 integrin in the mediation of these cell functions varies the same site on Vn as integrins and, therefore, compete depending on ECM substrate.
with integrins for Vn binding. Both uPAR and PAI-1 are It has frequently been observed that expression of the involved in SMC migration [30] [31] [32] . Furthermore, an a b integrin varies in human vascular SMCs in culture involvement of the plasminogen activator system in SMC may be required in order to maximise clinical potential. 
